Results 1 to 10 of about 6,701 (204)

HYDANTOIN DERIVATIVE

2012
HIMMLER THOMAS, FISCHER REINER, GALLENKAMP BERND, KNOPS HANS-JOACHIM, MULDER LUBBERTUS   +4 more
openaire   +1 more source

Hydantoin derivatives

1995
KOENIG WOLFGANG, ZOLLER GERHARD, JUST MELITTA, JABLONKA BERND   +3 more
openaire   +1 more source

Hydantoin manufacture

1945
openaire   +1 more source

Exploring hydantoin frameworks: synthetic approaches and therapeutic potential

Future Journal of Pharmaceutical Sciences
Background Since its first synthesis in the nineteenth century, hydantoin has emerged as a vital scaffold in drug development, especially for anticonvulsant, antimicrobial, antitumor, and anti-inflammatory agents.
Nirmala V. Shinde, Vrushali P. Patole, Manoj R. Kumbhare, Harsha Narkhede, Ashwini T. Satalkar, Anushka V. Thube, Sachin K. Bhosale   +6 more
doaj   +2 more sources

Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present) [PDF]

Molecules
Hydantoins, exemplified by the imidazolidine-2,4-dione core, are privileged scaffolds in medicinal chemistry due to their compact structure, versatile hydrogen-bonding capacity, ability to fine-tune physicochemical properties for drug-like molecules, and
Jyoti Dnyaneshwar Palkhede, Eo-Jin Park, Om Darlami, Dongyun Shin   +3 more
doaj   +2 more sources

Fetal Hydantoin Syndrome and Its Anaesthetic Implications: A Case Report [PDF]

Case Reports in Anesthesiology, 2012
Fetal hydantoin syndrome is a rare disorder that is believed to be caused by exposure of a fetus to the anticonvulsant drug phenytoin. The classic features of fetal hydantoin syndrome include craniofacial anomalies, prenatal and postnatal growth ...
Ranju Singh, Nishant Kumar, Sakshi Arora, Ritu Bhandari, Aruna Jain   +4 more
doaj   +2 more sources

Two siblings with fetal hydantoin syndrome

The Turkish Journal of Pediatrics, 1998
An association between anticonvulsant drugs taken during pregnancy and congenital abnormalities was first identified by Meadow et al. in 1968. Manson and Frederic clarified teratogenic effects of hydantoin in their epidemiological studies in 1973.
F Ozkinay, A Yenigün, M Kantar, C Ozkinay, A Avanoğlu, I Ulman   +5 more
doaj   +3 more sources

Hydantoin Derivatives of L- and D-amino acids: Synthesis and Evaluation of Their Antiviral and Antitumoral Activity

Molecules, 2006
3,5-Disubstituted hydantoin (1,3-imidazolidinedione) derivatives 5a-h wereprepared by base induced cyclization of the corresponding N-(1-benzotriazolecarbonyl)-L-and D-amino acid amides 4a-h.
Silvana Raić-Malić, Krešimir Pavelić, Erik de Clercq   +2 more
exaly   +3 more sources

Design, Synthesis, Bioevaluation, and Bioinformatics Study of 5‐Benzylidene Hydantoin Derivatives as Novel Tyrosine Kinase Inhibitors [PDF]

ChemistryOpen
Tyrosine kinases regulate cellular growth, differentiation, and metabolism, and their dysregulation is implicated in malignancies, making them therapeutic targets.
Muhammad Naufal, Elvira Hermawati, Ade Danova, Ika Wiani Hidayat, Jamaludin Al‐Anshori   +4 more
doaj   +2 more sources

Novel Dual 5-HT₇ Antagonists and Sodium Channel Inhibitors as Potential Therapeutic Agents with Antidepressant and Anxiolytic Activities [PDF]

Pharmaceuticals
Background/Objectives: The study aimed to pharmacologically evaluate dually acting ligands, 5-HT7 antagonists and sodium channel inhibitors, as potential therapeutic agents for the treatment of depression, anxiety, and neuropathic pain. The designed dual
Anna Czopek, Paulina Koczurkiewicz-Adamczyk, Katarzyna Wójcik-Pszczoła, Daria Kornas, Wojciech Sitko, Adam Bucki, Michał Sapa, Krzysztof Kamiński, Grzegorz Satała, Beata Duszyńska, Andrzej J. Bojarski, Gniewomir Latacz, Jacek Czopek, Joanna Szpor, Pola Dryja, Kinga Sałat   +15 more
doaj   +2 more sources